{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Onartuzumab+Placebo", "query": { "intervention": "Onartuzumab Placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 9, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-27T05:28:15.319Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01456325", "title": "A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Squamous Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Erlotinib", "type": "DRUG" }, { "name": "Onartuzumab (MetMab)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 494, "start_date": "2012-01", "completion_date": "2016-01", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-27T05:28:15.319Z", "location_count": 56, "location_summary": "Chandler, Arizona • Hayward, California • Modesto, California + 47 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Hayward", "state": "California" }, { "city": "Modesto", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01456325" }, { "nct_id": "NCT01519804", "title": "A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Squamous Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "cisplatin/carboplatin", "type": "DRUG" }, { "name": "onartuzumab", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 108, "start_date": "2012-04", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2016-09-02", "last_synced_at": "2026-09-27T05:28:15.319Z", "location_count": 34, "location_summary": "Huntsville, Alabama • Scottsdale, Arizona • Bakersfield, California + 28 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01519804" }, { "nct_id": "NCT01186991", "title": "Study Evaluating the Safety and Efficacy of Onartuzumab And/or Bevacizumab in Combination With Paclitaxel in Participants With Metastatic, Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Onartuzumab", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Bevacizumab Placebo", "type": "DRUG" }, { "name": "Onartuzumab Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 185, "start_date": "2011-03", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2017-01-20", "last_synced_at": "2026-09-27T05:28:15.319Z", "location_count": 23, "location_summary": "Bakersfield, California • Fullerton, California • Los Angeles, California + 19 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01186991" }, { "nct_id": "NCT01662869", "title": "A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "5-Fluoruracil", "type": "DRUG" }, { "name": "Folinic acid", "type": "DRUG" }, { "name": "Onartuzumab", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 564, "start_date": "2012-11", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-27T05:28:15.319Z", "location_count": 15, "location_summary": "Los Angeles, California • Denver, Colorado • Fort Myers, Florida + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01662869" }, { "nct_id": "NCT01418222", "title": "FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "5-FU", "type": "DRUG" }, { "name": "FOLFOX regimen", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "bevacizumab [Avastin]", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "onartuzumab [MetMAb]", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 194, "start_date": "2011-09-14", "completion_date": "2013-03-18", "has_results": false, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-09-27T05:28:15.319Z", "location_count": 23, "location_summary": "San Francisco, California • Denver, Colorado • Fort Myers, Florida + 19 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01418222" }, { "nct_id": "NCT01887886", "title": "A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Squamous Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "erlotinib", "type": "DRUG" }, { "name": "onartuzumab", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2013-12", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-27T05:28:15.319Z", "location_count": 15, "location_summary": "Bakersfield, California • Fullerton, California • Long Beach, California + 11 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01887886" }, { "nct_id": "NCT01496742", "title": "A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Squamous Non-Small Cell Lung Cancer" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "RO5490258", "type": "DRUG" }, { "name": "bevacizumab [Avastin]", "type": "DRUG" }, { "name": "cisplatin/carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Genentech, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 259, "start_date": "2012-04", "completion_date": "2015-11", "has_results": false, "last_update_posted_date": "2016-09-23", "last_synced_at": "2026-09-27T05:28:15.319Z", "location_count": 32, "location_summary": "Huntsville, Alabama • Scottsdale, Arizona • Bakersfield, California + 27 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Fullerton", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01496742" }, { "nct_id": "NCT01632228", "title": "A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab Compared to Bevacizumab Alone or Onartuzumab Monotherapy in Participants With Recurrent Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Onartuzumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 135, "start_date": "2012-06-29", "completion_date": "2016-01-21", "has_results": false, "last_update_posted_date": "2018-02-05", "last_synced_at": "2026-09-27T05:28:15.319Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01632228" }, { "nct_id": "NCT01590719", "title": "A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Gastric Cancer" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "Onartuzumab (MetMAb)", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Folinic acid", "type": "DRUG" }, { "name": "Levofolinic acid", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2012-07", "completion_date": "2014-10", "has_results": false, "last_update_posted_date": "2016-08-09", "last_synced_at": "2026-09-27T05:28:15.319Z", "location_count": 18, "location_summary": "Denver, Colorado • New Haven, Connecticut • Fort Myers, Florida + 15 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01590719" } ] }